期刊文献+

65例重症药物不良反应患者临床分析

Clinical analysis of 65 patients with severe adverse drug reactions
下载PDF
导出
摘要 回顾性分析我院2018年1月1日至2021年12月31日重症药物不良反应患者的临床资料,总结我院住院重症药物不良反应患者的临床特点、治疗及转归。结果示65例重症药物不良反应患者包括DRESS 15例,TEN 12例,SJS 7例,AGEP 23例,ED 8例,平均年龄(48.2±16.8)岁,男女比例0.38∶1,患者从应用致敏药物到发病平均潜伏期(13.5±14.4)天;致敏药物以抗感染药物(30.7%)及中成药(20.0%)为主;肝功能损害是最常见的伴随症状。31例患者采用单用糖皮质激素的常规治疗方案(组1);11例患者单用糖皮质激素疗效不佳或不能耐受激素副作用,给予糖皮质激素联合TNF-α拮抗剂治(组2);9例患者病情进展快速,症状严重,给予糖皮质激素联合TNF-α拮抗剂及静脉滴注免疫球蛋白治疗(组3);组4、组5各7例,病情相对较轻,分别给予单用TNF-α拮抗剂和环孢素治疗。组3患者皮损控制时间(7.4±1.3)天及平均住院时间(15.6±2.6)天分别低于组2的(9.5±2.6)天和(18.1±5.5)天(P<0.05),所有患者皮损控制平均时间(8.8±3.0)天,平均住院时间(16.8±4.4)天。患者出院半年后随访,58例患者痊愈,平均用药时间为(64.7±53.7)天,3例患者再次住院治疗,2例失访,2例患者死亡。 The clinical data of patients with severe adverse drug reactions in our hospital from January 1,2018 to December 31,2021 were analyzed to summarize the clinical characteristics,treatment and regression of severe adverse drug reactions.A total of 65 patients including 15 of DRESS,12 of TEN,7 of SJS,23 of AGEP and 8 of ED were analyzed.The mean age of was 48.2±16.8 years,with a male to female ratio of 0.38∶1.The mean incubation period from the application of allergenic drugs to the onset of disease was 13.5±14.4 days.The allergenic drugs were mainly anti-infective drugs(30.7%)and proprietary Chinese medicines(20.0%).The liver function impairment was the most common concomitant symptom.Patients were divided into five groups:31 patients in group 1 were treated with the conventional regimen of glucocorticoids alone.11 patients in group 2 were given glucocorticoids combined with TNF-αantagonists due to poor efficacy of glucocorticoids alone or intolerance of hormonal side effects.9 patients in group 3 who had rapid progression and severe symptoms were treated with glucocorticoids combined with TNF-αantagonists and intravenous immunoglobulin.14 patients with relatively mild manifestation were treated with TNF-αantagonist(7 patients)or cyclosporine alone(7 patients).The average duration of skin lesion control for all patients was 8.8±3.0 days and the average length of stay was 16.8±4.4 days.The mean time to lesion control(7.4±1.3 days)and mean hospital stay(15.6±2.6 days)were lower in group 3 than in group 2(9.5±2.6 days)and(18.1±5.5 days)(P<0.05).Follow-up 6 months after discharge,58 patients cured and,the average duration of medication was 64.7±53.7 days,3 cases received another hospitalization for recurrence,2 died,2 loss to follow-up.
作者 李红慧 赵晴 尤家宝 杨宝琦 杨青 施仲香 刘红 张福仁 LI Honghui;ZHAO Qing;YOU Jiabao;YANG Baoqi;YANG Qing;SHI Zhongxiang;LIU Hong;ZHANG Furen(Shandong University,Jinan 250012,China;Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and Venereology,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250022,China)
出处 《中国麻风皮肤病杂志》 2023年第5期332-337,共6页 China Journal of Leprosy and Skin Diseases
基金 山东省医药卫生科技发展计划(编号:202004120780) 山东省皮肤性病学临床医学研究中心 山东第一医科大学学术提升计划(编号:2019LJ002)。
关键词 重症药物不良反应 糖皮质激素 TNF-α拮抗剂 IVIG severe adverse drug reactions glucocorticoids tumour necrosis factor antagonists intravenous immunoglobulin
  • 相关文献

参考文献5

二级参考文献24

  • 1王侠生,孙清娟.重症药疹104例临床分析[J].临床皮肤科杂志,1993,22(4):187-189. 被引量:58
  • 2Bastuji-Garin S, Rzany B, Stem RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 1993, 129 ( 1 ): 92-96. 被引量:1
  • 3Bastuji-Garin S, Fouchard N, Bertocehi M, et al. SCORTEN: a severity of illness score for toxic epidermal neerolysis. J Invest Dermatol, 2000, 115(2): 149-153. 被引量:1
  • 4Imahara SD, Holmes JH, Heirnbaeh DM, et al. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J Burn Care Res, 2006, 27(3 ): 270-275. 被引量:1
  • 5Cartotto R, Mayich M, Nickerson N, et al. SCORTEN Accurately Predicts Mortality Among Toxic Epidermal Neerolysis Patients Treated in a Burn Center. J Bum Care Res, 2008, 29 (1): 141-146. 被引量:1
  • 6Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN During the First Five Days of Hospitalization to Predict the Prognosis of Epidermal Necrolysis. J Invest Dermatol, 2006, 126(2): 272-276. 被引量:1
  • 7Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol, 2004, 140(7): 890- 892. 被引量:1
  • 8Liddell FD. Simple exact analysis of the standardized mortality ratio. J Epidemiol Community Health, 1984, 38( 1 ): 85-88. 被引量:1
  • 9Khalili B, Bahna SL. Pathogancsis and recent therapoutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol, 2006, 97(3 ): 272-280. 被引量:1
  • 10Gerdts B, Vloemans AF, Kreis RW. Toxic epidermal neerolysis; 15 years' experience in a Dutch bums centre. J Ettr Aead Dermatol Venereol, 2007, 21(6): 781-788. 被引量:1

共引文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部